Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (101-110 of 314) with videos related to

Pageof 32
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|March 22, 2023
Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical ConsiderationsSneha Butala, Leslie Castelo-Soccio, Rishi Seshadri, et al.
The Journal of Dermatology|October 13, 2023
Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapyEric L Simpson, Leon Kircik, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|February 13, 2017
Understanding the cost of dermatologic care: A survey study of dermatology providers, residents, and patientsAaron J Steen, Julianne A Mann, Valerie M Carlberg, et al.
The Journal of Dermatological Treatment|June 21, 2021
Low-dose methotrexate in dermatology: the utility of serological monitoring in a real-world cohortTamar Hajar, Emile J Latour, Dylan Haynes, et al.
Journal of the American Academy of Dermatology|December 15, 2018
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trialEric L Simpson, Jane R Parnes, Dewei She, et al.
Dermatology and Therapy|November 5, 2022
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)Jonathan I Silverberg, Eric L Simpson, Brian M Calimlim, et al.
Dermatology and Therapy|February 4, 2025
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DAREJonathan I Silverberg, Eric L Simpson, Andrew E Pink, et al.
American Journal of Clinical Dermatology|October 26, 2021
Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, April W Armstrong, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 17, 2022
Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)Eric L Simpson, Andreas Wollenberg, Weily Soong, et al.
The Journal of Dermatological Treatment|February 1, 2024
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studiesEric L Simpson, Robert Bissonnette, Zelma C Chiesa Fuxench, et al.
Pageof 32

Showing results (101-110 of 314) with videos related to

Sort By:
Pageof 32
The Journal of Allergy and Clinical Immunology. in Practice|March 22, 2023
Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical ConsiderationsSneha Butala, Leslie Castelo-Soccio, Rishi Seshadri, et al.
The Journal of Dermatology|October 13, 2023
Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapyEric L Simpson, Leon Kircik, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|February 13, 2017
Understanding the cost of dermatologic care: A survey study of dermatology providers, residents, and patientsAaron J Steen, Julianne A Mann, Valerie M Carlberg, et al.
The Journal of Dermatological Treatment|June 21, 2021
Low-dose methotrexate in dermatology: the utility of serological monitoring in a real-world cohortTamar Hajar, Emile J Latour, Dylan Haynes, et al.
Journal of the American Academy of Dermatology|December 15, 2018
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trialEric L Simpson, Jane R Parnes, Dewei She, et al.
Dermatology and Therapy|November 5, 2022
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)Jonathan I Silverberg, Eric L Simpson, Brian M Calimlim, et al.
Dermatology and Therapy|February 4, 2025
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DAREJonathan I Silverberg, Eric L Simpson, Andrew E Pink, et al.
American Journal of Clinical Dermatology|October 26, 2021
Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, April W Armstrong, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 17, 2022
Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)Eric L Simpson, Andreas Wollenberg, Weily Soong, et al.
The Journal of Dermatological Treatment|February 1, 2024
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studiesEric L Simpson, Robert Bissonnette, Zelma C Chiesa Fuxench, et al.
Pageof 32